ORTHO-NOVUM 1/35-28
LOE ApproachingNDAORAL-28TABLET
Approved
Jun 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 1/35-28 is an oral contraceptive tablet combining norethindrone and ethinyl estradiol in a 28-day cyclic regimen. It prevents pregnancy through hormonal suppression of ovulation. This product represents a foundational oral contraceptive from the 1970s era.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity); expect declining team investment and focus on legacy brand management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO-NOVUM 1/35-28 represents a mature-stage, defensive portfolio role within Johnson & Johnson's legacy franchises. Career trajectory is limited; positions typically focus on maintaining market share and managing generic erosion rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on ORTHO-NOVUM 1/35-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.